Management and risk factors for mortality in very elderly patients with acute myocardial infarction
Alfredo Renilla1, Manuel Barreiro, Vicente Barriales
1Department of Cardiology, University Central Hospital of Asturias, Oviedo, Spain. dr.renilla@gmail.com
Insights
Very elderly patients with ST-segment elevation myocardial infarction (STEMI) face high mortality and morbidity. Reperfusion therapies significantly reduce these risks, with heart failure on admission being a key predictor of mortality.
Area of Science:
- Cardiology
- Geriatric Medicine
- Clinical Research
Background:
- Elderly individuals are often underrepresented in clinical trials.
- ST-segment elevation myocardial infarction (STEMI) in patients aged 85 years and older presents unique challenges.
Purpose of the Study:
- To analyze treatment strategies, clinical outcomes, and mortality risk factors in very elderly patients (≥85 years) with STEMI.
- To evaluate the impact of reperfusion strategies on morbidity and mortality in this demographic.
Main Methods:
- Retrospective review of 102 patients aged ≥85 years with STEMI from 2005-2011.
- Analysis of clinical data, treatment received (primary angioplasty, fibrinolysis, conservative), and in-hospital outcomes.
- Multivariate analysis to identify independent risk factors for mortality.
Main Results:
- The mean age was 87.5 years; 28.4% of patients died, and 61.7% experienced morbidity.
- Reperfusion strategies (primary PCI or fibrinolysis) were associated with significantly lower morbidity (53.7%) and mortality (17.9%) compared to conservative treatment (77.1% morbidity, 48.5% mortality).
- Heart failure on admission was identified as an independent risk factor for hospital mortality (OR=3.64).
Conclusions:
- Mortality and morbidity rates are notably high in very elderly STEMI patients.
- Reperfusion therapies are crucial for improving outcomes in this population.
- Early identification and management of heart failure in elderly STEMI patients are critical for reducing mortality.
Aim:
Elderly patients often remain underrepresented in clinical trials. The aim of our study was to analyze the treatment, clinical outcome and risk factors for mortality in patients aged ≥85 years with ST-segment elevation myocardial infarction (STEMI).
Methods:
From 2005-2011, 102 patients aged ≥85 years with STEMI admitted to a coronary care unit were retrospectively reviewed. Clinical data, treatment and outcome were recorded. Reperfusion strategy and its influence in hospital morbidity and mortality were evaluated. Morbidity was defined as the presence of heart failure (Killip-Kimball >1), arrhythmias, mechanical complications, stroke or major bleeding. Risk factors for mortality were assessed by multivariate analysis.
Results:
The mean age was 87.5±2.5 years (range 85-96). Therapeutic strategy on admission was: primary-angioplasty (PCI) for 33 patients (32.3%) fibrinolysis for 30 patients (29.4%) and conservative treatment for 35 patients (34.3%). In the four remaining patients, rescue angioplasty was required. A total of 29 patients (28.4%) died, and morbidity was seen in 63 patients (61.7%). The morbidity and mortality rates in the conservative treatment group (77.1% and 48.5%) were higher than that found in the reperfusion strategy group (primary-PCI and fibrinolysis; 53.7% and 17.9%; P=0.02 and P=0.002, respectively). Regarding mortality, the univariate analysis showed that heart failure on admission (P=0.0001) and previous coronary artery disease (P=0.01) were prognostic variables. Only heart failure was an independent risk factor for mortality (odds ratio=3.64, 95% CI 0.78-21.87, P<0.0001).
Conclusions:
Mortality and morbidity in very elderly patients with STEMI are very high, especially in those not receiving reperfusion therapies. Heart failure on admission was an independent risk factor for hospital mortality.
Related Concept Videos
Acute Coronary Syndrome IV: Interprofessional Care
Acute Coronary Syndrome V: Nursing Management
Angina IV: Management
Angina V: Nursing Management
Acute Coronary Syndrome I: Introduction
Myocarditis III: Medical Management
